Defense Stock Domin...
Health Care: Drugs
Rigel Pharmaceuticals Inc. (RIGL: NASDAQ)
$4.72 0.08 | 1.72%
05/24/13 - 11:40 AM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.25M | 4.75M | 125.00M | 750.00K |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -1.40M |
| Gross Operating Profit | 2.25M | 4.75M | 125.00M | 2.15M |
| Selling, General, and Administrative Expenses | 22.85M | 21.77M | 25.29M | 20.90M |
| Research & Development | 78.78M | 69.35M | 64.39M | 90.74M |
| Operating Income before D & A (EBITDA) | -99.38M | -86.37M | 35.32M | -109.49M |
| Depreciation & Amortization | 2.43M | 1.96M | 1.32M | 1.40M |
| Interest Income | 537.00K | 420.00K | 303.00K | 600.00K |
| Other Income - Net | 0.00 | 0.00 | 2.36M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -101.27M | -87.90M | 36.66M | -111.44M |
| Interest Expense | 0.00 | 25.00K | 91.00K | 203.00K |
| Pre-Tax Income | -101.27M | -87.93M | 36.57M | -111.64M |
| Income Taxes | 0.00 | 0.00 | 0.00 | -93.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -98.84M | -85.97M | 37.89M | -111.55M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -98.84M | -85.97M | 37.89M | -111.55M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -98.84M | -85.97M | 37.89M | -111.55M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-98.84M | -85.97M | 37.89M | -110.41M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -98.84M | -85.97M | 37.89M | -111.55M |
| Basic EPS from Continuing Ops. | -1.32 | -1.36 | 0.73 | -2.73 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.32 | -1.36 | 0.73 | -2.73 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.32 | -1.36 | 0.73 | -2.73 |
| Basic Normalized Net Income/Share | -1.32 | -1.36 | 0.73 | -2.70 |
| EPS fr Continuing Ops. | -1.32 | -1.36 | 0.72 | -2.73 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.32 | -1.36 | 0.72 | -2.73 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.32 | -1.36 | 0.72 | -2.73 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.32 | -1.36 | 0.72 | -2.70 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with RIGL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest RIGL Headlines from TheStreet
- Rigel Pharmaceuticals Becomes Oversold (RIGL) 05.03.13 | 04:05 pm
- 5 Health Care Stocks Under $10 Ready to Rip Higher 04.18.13 | 09:04 pm
- 5 Stocks Poised for Breakouts 04.12.13 | 01:04 pm
- Frail Jobs Gains Gives Markets Jitters 04.05.13 | 04:04 pm
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- 3 Stocks Under $10 Making Big Moves 03.15.13 | 07:03 am
- Stocks Under $10: Blossoming Biotech Play
09.25.12 | 06:09 am - The Next Big Thing in Biotech: Pfizer 05.04.12 | 06:05 am
- Biotech Calendar: Key Dates for October 10.03.11 | 08:10 am
- Vertex Arthritis Pill Shines in Mid-Stage Study 09.06.11 | 08:09 am
Press Releases for RIGL
- Rigel's R348 To Initiate Phase 2 Clinical Trial In Dry Eye - PR Newswire 05.22.13 | 07:05 am
- Rigel Announces Participation At Two Investor Conferences - PR Newswire 02.28.13 | 07:02 am
- Rigel To Present At BIO CEO & Investor Conference - PR Newswire 02.07.13 | 07:02 am
- Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation - PR Newswire 01.03.13 | 07:01 am
- AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis - PR Newswire 12.13.12 | 07:12 am
- Rigel To Present At Jefferies 2012 Global Healthcare Conference In London - PR Newswire 11.08.12 | 07:11 am
- Rigel Announces Pricing Of Public Offering Of Common Stock - PR Newswire 10.03.12 | 09:10 am
- Rigel Announces Proposed Public Offering Of Common Stock - PR Newswire 10.02.12 | 04:10 pm
- Rigel To Present At UBS Global Life Sciences Conference - PR Newswire 09.17.12 | 07:09 am
- Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus - PR Newswire 09.05.12 | 07:09 am
Partner Headlines for RIGL
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 12.14.12 | 08:12 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Rigel Refuels R&D in $130M Offering - Seeking Alpha 05.29.11 | 08:05 am
- CORRECTED - CORRECTED-BRIEF-Rigel earns $25 million from Astrazeneca - Reuters 09.29.10 | 07:09 am
- AstraZeneca signs arthritis drug deal - Financial Times 02.16.10 | 06:02 pm
- Rigel sees partner for psoriasis drug in 3 months - COO - Reuters 02.16.10 | 03:02 pm
